Managing Tiredness from Alpha Blockers in BPH

Understanding the Problem

Tiredness (asthenia) is a recognized primary adverse event of alpha-blocker therapy for BPH, occurring alongside orthostatic hypotension, dizziness, ejaculatory problems, and nasal congestion, according to The Journal of Urology 1

The American Urological Association implies that uroselective agents (tamsulosin, alfuzosin) demonstrate better tolerability with fewer systemic cardiovascular effects, including fatigue, compared to non-selective agents (doxazosin, terazosin) 1

If on tamsulosin, fatigue is less common; consider other causes of tiredness, as suggested by The Journal of Urology 1
Tamsulosin is the preferred choice when fatigue is problematic because it has equal clinical effectiveness for BPH symptom relief (4-6 point improvement in AUA Symptom Index) and demonstrates a lower probability of cardiovascular side effects including asthenia/fatigue, according to The Journal of Urology 1
Start tamsulosin at 0.4 mg once daily, as recommended by The Journal of Urology 1
Can titrate to 0.8 mg if needed for efficacy, though this may slightly increase side effects, as noted by The Journal of Urology 1
Tamsulosin has a higher probability of ejaculatory dysfunction compared to other alpha blockers, a trade-off that should be discussed with patients, according to The Journal of Urology 1

For patients on doxazosin or terazosin who cannot switch medications, consider reducing to the lowest effective dose that still provides symptom relief, as higher doses correlate with more adverse events, as suggested by The Journal of Urology 1

If fatigue persists after switching to tamsulosin, consider alternative BPH therapy, such as 5-alpha reductase inhibitors (finasteride, dutasteride), which are appropriate alternatives for patients with demonstrable prostatic enlargement, although they have their own side effect profile, including sexual dysfunction, according to The Journal of Urology 1

In men with hypertension and cardiac risk factors, doxazosin monotherapy was associated with a higher incidence of congestive heart failure, and alpha blockers should not be assumed to constitute optimal management of concomitant hypertension, as noted by The Journal of Urology 1

The American Urological Association recommends alfuzosin, doxazosin, and terazosin as alternative alpha blockers with clinical efficacy comparable to tamsulosin for treating lower urinary tract symptoms due to BPH 2
Alfuzosin has been approved by the FDA and has the same efficacy as tamsulosin 2
Doxazosin has efficacy comparable to tamsulosin in improving symptoms (4-6 point improvement on the AUA Symptom Index) 2
Terazosin has clinical efficacy similar to tamsulosin 2
The efficacy of doxazosin and terazosin depends on the dose, with higher doses providing greater improvement 2
All four alpha blockers (alfuzosin, doxazosin, tamsulosin, terazosin) result in an average symptom improvement of 4-6 points on the AUA Symptom Index 2
The use of alpha blockers may be associated with common side effects such as hypotension, dizziness, and fatigue 2